Giselle L. Saulnier Sholler

Author

Also Known As

G. L. Saulnier Sholler, G. Saulnier Sholler, G. Sholler, Giselle L Saulnier Sholler, Giselle L. Saulnier Sholler, Giselle L. Saulnier Sholler, Giselle L. Sholler, Giselle L.S. Sholler, Giselle S Sholler, Giselle S. Sholler

120

Publications

1.2K

Citations

H-Index

Concepts

All Affiliations

University of Vermont Helen DeVos Children's Hospital Levine Children's Hospital Medical University of South Carolina University of California San Diego

About

Giselle L. Saulnier Sholler is an author at University of Vermont specializing in medicine, radiation oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	297
2	Cell Biology	3	3	161
3	Health Sciences	2	2	79
4	Immunology	1	1	31
5	Neurology	1	1	62

Giselle L. Saulnier Sholler

Publications

1.1K

Citations

H-Index

Page 1

	Year	Citations
A Phase I Trial of DFMO Targeting Polyamine Addiction in Patients with Relapsed/Refractory Neuroblastoma Giselle L. Saulnier Sholler, Eugene W. Gerner, Genevieve Bergendahl, PLoS ONE	2015	139
Maintenance DFMO Increases Survival in High Risk Neuroblastoma Giselle L. Saulnier Sholler, William S. Ferguson, Genevieve Bergendahl, Scientific Reports	2018	101
AMXT-1501, a novel polyamine transport inhibitor, synergizes with DFMO in inhibiting neuroblastoma cell proliferation by targeting both ornithine decarboxylase and polyamine transport Katherine Samal, Ping Zhao, Ann Kendzicky, International Journal of Cancer Polyamine TransportRetinoblastoma ProteinGliomaTumor BiologyNb Cell Lines	2013	93
Targeting ornithine decarboxylase reverses the LIN28/Let-7 axis and inhibits glycolytic metabolism in neuroblastoma Ann Lozier, Maria Rich, Anissa Pedersen Grawe, Oncotarget	2014	64
A subset analysis of a phase <scp>II</scp> trial evaluating the use of <scp>DFMO</scp> as maintenance therapy for high‐risk neuroblastoma Elizabeth C. Lewis, Jacqueline M. Kraveka, William S. Ferguson, International Journal of Cancer High‐risk NeuroblastomaCancer ManagementDfmo MaintenanceNeurological ProgressSubset Analysis	2020	62
Eflornithine as Postimmunotherapy Maintenance in High-Risk Neuroblastoma: Externally Controlled, Propensity Score–Matched Survival Outcome Comparisons Javier Oesterheld, William S. Ferguson, Jacqueline M. Kraveka, Journal of Clinical Oncology	2023	58
A Phase 1 Study of Nifurtimox in Patients With Relapsed/Refractory Neuroblastoma Giselle L. Saulnier Sholler, Genevieve Bergendahl, Laurent Brard, Journal of Pediatric Hematology/Oncology	2010	51
Nifurtimox Induces Apoptosis of Neuroblastoma Cells In Vitro and In Vivo Giselle L. Saulnier Sholler, Laurent Brard, Jennifer A. Straub, Journal of Pediatric Hematology/Oncology Cell DeathPathologyGliomaNeuroblastoma CellsTumor Biology	2009	41
Antitumor Activity of Nifurtimox Observed in a Patient With Neuroblastoma Giselle L. Saulnier Sholler, Satyan Kalkunte, Carla Greenlaw, Journal of Pediatric Hematology/Oncology	2006	34
Tolfenamic acid inhibits neuroblastoma cell proliferation and induces apoptosis: A novel therapeutic agent for neuroblastoma Don Eslin, Umesh T. Sankpal, Chris Lee, Molecular Carcinogenesis	2011	34

Page 1